Lv3
310 积分 2025-06-06 加入
Role of Neoadjuvant Immune Checkpoint Inhibitors in Locally Advanced Rectal Cancer: A Systematic Review of Currently Available Studies
7天前
已完结
Prognostic Value of MicroRNAs in Stage II Colorectal Cancer Patients: A Systematic Review and Meta-Analysis
7天前
已完结
Assessment of the Addition of Oxaliplatin to Fluoropyrimidine-Based Adjuvant Chemotherapy in Patients With High-Risk Stage II Colon Cancer: An ACCENT Pooled Analysis
11天前
已完结
Postoperative chemotherapy improves survival in patients with resected high‐risk Stage II colorectal cancer: results of a systematic review and meta‐analysis
1个月前
已完结
Rechallenge with cetuximab + irinotecan in 3rd-line in RAS and BRAF wild-type metastatic colorectal cancer (mCRC) patients with acquired resistance to 1st-line cetuximab+irinotecan: The phase II CRICKET study by GONO
1个月前
已完结
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
1个月前
已完结
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
1个月前
已完结
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial
1个月前
已完结
Abstract CT217: OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided RAS/BRAF wild-type metastatic colorectal cancer
1个月前
已完结
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
1个月前
已完结
皖公网安备34019202002308
